Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCYQJF)

Drug Name
L-741626 Drug Info
Synonyms
L-741,626; 81226-60-0; L-741626; 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole; L 741626; L 741,626; CHEMBL445102; 4-(4-Chlorophenyl)-1-(1H-indol-3-ylmethyl)-4-piperidinol; 4-(4-chlorophenyl)-1-(1h-indol-3-ylmethyl)piperidin-4-ol; C20H21ClN2O; 4-Piperidinol, 4-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)-; SR-01000075973; Tocris-1003; NCGC00015591-01; Lopac-L-135; Biomol-NT_000036; AC1Q3NO6; Lopac0_000742; GTPL177; MLS000860079; ZINC6788; BPBio1_001094; AC1L335F; SCHEMBL11253588; CHEBI:92090; CTK3I9542; DTXSID30230974
Cross-matching ID
PubChem CID
133633
ChEBI ID
CHEMBL92090
CAS Number
CAS 81226-60-0
TTD Drug ID
D0M3PV

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.52 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis 2.04 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
Synthesis and degradation of ketone bodies 1.99 7.74e-3 9/10 (90%) HMGCS1;ACAT2
Steroid hormone biosynthesis 1.95 1.45e-2 43/61 (70.49%) HSD17B7;AKR1C2;AKR1C1;...
PPAR signaling pathway 1.92 1.16e-2 66/74 (89.19%) SCD;HMGCS1;FABP4;...
Retinol metabolism 1.89 2.13e-2 41/68 (60.29%) RDH11;DHRS3;AOX1;...
Lysosome 1.79 4.31e-2 115/128 (89.84%) MCOLN1;NEU1;ATP6AP1;...
GnRH secretion 1.78 3.77e-2 60/64 (93.75%) MAP2K2;PLCB1;ARRB2;...
AMPK signaling pathway 1.76 4.00e-2 106/120 (88.33%) SCD;HMGCR;ACACA;...
Biosynthesis of unsaturated fatty acids 1.74 4.99e-2 21/27 (77.78%) SCD;FADS1;FADS2;...
Cell cycle -1.74 3.83e-2 110/124 (88.71%) SFN;EP300;TFDP2;...
DNA replication -1.77 3.61e-2 34/36 (94.44%) RPA2;MCM5;PCNA;...
RNA polymerase -1.79 3.48e-2 23/31 (74.19%) POLR2K;POLR3D;POLR3B;...
Spliceosome -1.90 1.09e-2 101/150 (67.33%) SNU13;PRPF38B;SNRPF;...
Ribosome biogenesis in eukaryotes -1.98 8.20e-3 52/108 (48.15%) SNU13;GTPBP4;POP7;...
Mineral absorption -2.62 0.00e+0 48/60 (80%) ATP1B3;SLC26A3;SLC30A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H